BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, March 28, 2024
See today's BioWorld
Home
» Remynd raises $14M for first-in-class calcium modulator in Alzheimer's
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Remynd raises $14M for first-in-class calcium modulator in Alzheimer's
Dec. 18, 2018
By
Cormac Sheridan
No Comments
DUBLIN – Remynd NV raised €12 million (US$13.6 million) in a series B round that will enable it to move a first-in-class modulator of intracellular calcium levels into clinical development in Alzheimer's disease.
BioWorld